Abstract 56: S14161 Inhibits Platelet Activation and Thrombus Formation via PI3K Signaling Pathway
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is critical in modulating platelet functions. In the present study, we evaluated the effect of S14161, a recently identified pan-class I PI3K inhibitor, on platelet activation and thrombus formation. Results showed that S14161 inhibited human platelet aggregation induced by collagen, thrombin, U46619, and ADP in a dose-dependent manner. For example, the maximal aggregation induced by collagen were decreased by 32.7% (P<0.05), 59.4% (P<0.001) and 89.2% (P<0.001) (IC50=3.79±1.17 μM) when preincubated with 2.5, 5 and 10 μM of S14161, respectively. Interestingly, platelet aggregates were disaggregated after the peak of aggregation induced by ADP when platelets were pretreated with S14161 (10 μM). S14161 also inhibited platelet aggregation induced by GPVI selective ligand convulxin and CRP, PAR1 agonist SFLLRN, and calcium ionophore A23187. Flow cytometric studies showed that S14161 inhibited convulxin-induced P-selectin expression and fibrinogen binding of single platelet. S14161 also inhibited platelet spreading on fibrinogen and clot retraction, processes mediated by outside-in signaling. Using a microfluidic chamber we demonstrated that S14161 decreased platelet adhesion on collagen-coated surface by about 80%. Western blot showed that S14161 inhibited phosphorylation of Akt at both Ser473 and Thr308 sites, and GSK3β at Ser9 in response to collagen, thrombin, or U46619. Additionally, S14161 inhibited ERK1/2 activation. Finally, the effects of S14161 on thrombus formation in vivo were measured using a ferric chloride-induced carotid artery injury model in mice. The intraperitoneal injection of S14161 (2 mg/kg) to male C57BL/6 mice significantly extended the first occlusion time (5.05±0.99 min, n=9) compared to the vehicle controls (3.72±0.95 min, n=8) (P<0.05), but did not prolong the bleeding time (P>0.05). Taken together, our data showed that S14161 inhibits platelet activation and thrombus formation, and may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.
Author Disclosures: W. Yi: None. X. Mao: None. L. Zhu: None.
- © 2014 by American Heart Association, Inc.